방사선의학 웹진

바로가기  >

Abstract

The usefulness of(18)F-FDG PET in gastric cancer recurrence is limited by low sensitivity. Given that detectability by PET is dependent on the tumor's metabolic characteristics, we tested whether the performance of PET for gastric cancer recurrence is enhanced in patients with(18)F-FDG-avid primary tumors.

METHODS:

Three hundred sixty-eight patients with advanced gastric cancer underwent(18)F-FDG PET/CT for initial staging and for recurrence surveillance after curative surgery. On initial PET/CT, primary tumors were(18)F-FDG-avid if they displayed focal uptake with an SUVmax4 or more. Follow-up(18)F-FDG PET/CT was evaluated for recurrent disease.

RESULTS:

On initial PET/CT, the primary tumor was(18)F-FDG-avid in 236 of 368 (64.1%) and nonavid in 132 patients (35.9%). During follow-up for 18.9 ± 13.3 mo, 72 patients (19.6%) had recurrence. Of the 63 PET scans with recurrence, 42 (66.7%) and 21 (33.3%) were scans of patients with(18)F-FDG-avid and nonavid primary tumors, respectively. PET sensitivity was higher in scans of patients with(18)F-FDG-avid than nonavid tumors for all recurrences (81.0% vs. 52.4%;P= 0.018) and nonanastomosis site recurrences (82.1% vs. 47.4%;P= 0.006). The sensitivity for detecting peritoneal recurrence was also higher for the avid tumor group. PET specificity was similarly high (97.1% and 97.5%) for both groups. Adding cell type and Lauren classification to tumor(18)F-FDG avidity further enhanced PET sensitivity.

CONCLUSION:

Surveillance(18)F-FDG PET/CT after resection of gastric cancer has significantly higher sensitivity in patients with(18)F-FDG-avid primary tumors and may have greater value in this group. 

Author information​

Kim SJ1, Cho YS1, Moon SH1, Bae JM2, Kim S2, Choe YS1, Kim BT1, Lee KH3.

1Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; and.

2Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

3Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; and khnm.lee@samsung.com.